FRES: AI 评分 50/100 — AI 分析 (4月 2026)

Fresh2 Group Limited is a biotechnology company focused on multi-cancer screening and detection in China. They utilize cancer differentiation analysis technology and operate an e-commerce platform connecting food suppliers with supermarket operators and restaurant owners.

Key Facts: AI Score: 50/100 Sector: Healthcare

公司概况

概要：

Fresh2 Group Limited is a biotechnology firm specializing in multi-cancer screening and detection technologies, primarily serving corporations and life insurance companies in China. The company also offers physical checkup packages, genetic testing kits, and operates an e-commerce platform, positioning it as a diversified player in the healthcare and food supply chain sectors.

FRES是做什么的？

Fresh2 Group Limited, formerly known as AnPac Bio-Medical Science Co., Ltd., was founded in 2010 and rebranded in April 2023. The company is headquartered in New York City and focuses on researching, developing, marketing, and selling multi-cancer screening and detection tests. These tests utilize cancer differentiation analysis technology and devices, targeting corporations and life insurance companies in the People's Republic of China. Beyond its core cancer screening business, Fresh2 Group offers physical checkup packages and technology services, including market research, designing, coding, developing, and testing. The company also sells genetic testing kits and skin-care products, leveraging its core technology platforms for product development and distribution. Furthermore, Fresh2 Group operates an e-commerce platform designed to connect food suppliers with supermarket operators and restaurant owners, diversifying its business interests beyond healthcare. The company has 75 employees.

FRES的投资论点是什么？

Fresh2 Group Limited presents a speculative investment opportunity within the biotechnology sector, primarily focused on the Chinese market. The company's multi-cancer screening technology and e-commerce platform offer potential growth avenues. However, the company's negative profit margin of -846.0% and a market capitalization of $0.00B suggest significant financial challenges. Key catalysts include successful commercialization of its cancer screening tests and expansion of its e-commerce platform. Potential risks include regulatory hurdles in China, competition from established players, and the company's current financial instability. Investors should carefully consider these factors before investing.

FRES在哪个行业运营？

Fresh2 Group Limited operates in the biotechnology and healthcare sectors, which are characterized by rapid innovation and intense competition. The multi-cancer screening market is experiencing growth due to increased awareness and demand for early detection. However, the company faces competition from established players and must navigate regulatory challenges in China. The e-commerce platform adds another layer of complexity, placing the company in competition with established online marketplaces and food supply chain companies. The biotechnology industry is projected to grow at a CAGR of 12% through 2030, driven by technological advancements and increasing healthcare expenditure.

Biotechnology

Healthcare

FRES有哪些增长机遇？

Expansion of Cancer Screening Services in China: The increasing demand for early cancer detection in China presents a significant growth opportunity for Fresh2 Group. By leveraging its cancer differentiation analysis technology, the company can target corporations and life insurance companies, offering comprehensive screening packages. The Chinese cancer diagnostics market is projected to reach $5 billion by 2028, providing a substantial addressable market for Fresh2 Group.
E-commerce Platform Growth: The company's e-commerce platform connecting food suppliers with supermarket operators and restaurant owners offers diversification and growth potential. By expanding its network of suppliers and customers, Fresh2 Group can capitalize on the growing demand for efficient food supply chain solutions. The Chinese e-commerce market is the largest in the world, with food and beverage representing a significant segment.
Strategic Partnerships: Forming strategic alliances with hospitals, clinics, and healthcare providers in China can accelerate the adoption of Fresh2 Group's cancer screening services. These partnerships can provide access to a broader patient base and enhance the company's credibility. Collaborations with established healthcare institutions can also facilitate regulatory approvals and market access.
Product Diversification: Expanding the product portfolio to include additional diagnostic tests and healthcare services can drive revenue growth. By leveraging its technology platforms, Fresh2 Group can develop new tests for other diseases and conditions, catering to a wider range of healthcare needs. This diversification can reduce reliance on the cancer screening market and mitigate risks associated with regulatory changes.
Geographic Expansion: While currently focused on China, Fresh2 Group can explore opportunities to expand its cancer screening services to other Asian markets with similar healthcare needs and demographics. This geographic expansion can diversify revenue streams and reduce reliance on the Chinese market. Countries like India and Southeast Asian nations offer significant growth potential for cancer diagnostics.

Market capitalization of $0.00B indicates a micro-cap company with high volatility.
Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
Profit margin of -846.0% highlights significant operational inefficiencies and high expenses.
Gross margin of 69.2% suggests potential for profitability if operational costs are managed effectively.
Beta of 1.28 indicates higher volatility compared to the overall market.

FRES提供哪些产品和服务？

Researches and develops multi-cancer screening and detection tests.
Markets and sells cancer screening tests to corporations and life insurance companies in China.
Offers physical checkup packages.
Provides technology services including market research, designing, coding, developing, and testing.
Sells genetic testing kits and skin-care products.
Operates an e-commerce platform connecting food suppliers with supermarket operators and restaurant owners.
Engages in technology development and product distribution.

FRES如何赚钱？

Generates revenue from the sale of multi-cancer screening and detection tests.
Earns income from physical checkup packages and technology services.
Derives revenue from the sale of genetic testing kits and skin-care products.
Collects fees from transactions on its e-commerce platform.

Corporations in China seeking employee health benefits.
Life insurance companies in China offering cancer screening as part of their policies.
Individuals purchasing physical checkup packages and genetic testing kits.
Supermarket operators and restaurant owners sourcing food supplies through the e-commerce platform.

Proprietary cancer differentiation analysis technology.
Established relationships with corporations and life insurance companies in China.
Diversified business model with revenue streams from healthcare and e-commerce.
E-commerce platform provides a unique offering in connecting food suppliers with businesses.

什么因素可能推动FRES股价上涨？

Upcoming: Successful clinical trials and regulatory approvals for its cancer screening technologies in China.
Ongoing: Expansion of the e-commerce platform and increased transaction volume.
Ongoing: Strategic partnerships with hospitals and healthcare providers in China.
Upcoming: Product diversification into new diagnostic tests and healthcare services.

FRES的主要风险是什么？

Potential: Regulatory changes and uncertainties in China impacting the healthcare and e-commerce sectors.
Ongoing: Intense competition from established players in the biotechnology and e-commerce sectors.
Potential: Economic slowdown in China impacting consumer spending and healthcare demand.
Ongoing: Technological advancements rendering existing technologies obsolete.
Ongoing: The company's significant financial losses and negative profit margin raise concerns about its long-term viability.

FRES的核心优势是什么？

Proprietary cancer differentiation analysis technology.
Diversified business model with healthcare and e-commerce operations.
Established presence in the Chinese market.
Experienced management team with expertise in biotechnology and e-commerce.

FRES的劣势是什么？

Negative profit margin and significant financial losses.
Limited market capitalization and high volatility.
Reliance on the Chinese market and regulatory environment.
Intense competition in both the biotechnology and e-commerce sectors.

FRES有哪些机遇？

Expansion of cancer screening services in China.
Growth of the e-commerce platform connecting food suppliers with businesses.
Strategic partnerships with hospitals and healthcare providers.
Product diversification into new diagnostic tests and healthcare services.

FRES面临哪些威胁？

Regulatory changes and uncertainties in China.
Competition from established players in the biotechnology and e-commerce sectors.
Economic slowdown in China impacting consumer spending.
Technological advancements rendering existing technologies obsolete.

FRES的竞争对手是谁？

ASLAN Pharmaceuticals Limited — Focuses on immunology and oncology therapeutics. — (ASLN)
Cutera, Inc. — Develops and markets energy-based aesthetic systems. — (CUTR)
Eiger BioPharmaceuticals, Inc. — Focuses on developing therapies for serious diseases. — (EIGRQ)
Midatech Pharma PLC — Develops drug delivery technologies and products. — (MTP)
Neurotrope, Inc. — Focuses on developing therapies for neurodegenerative diseases. — (NTBL)

Key Metrics

MoonshotScore: 50/100

Company Profile

CEO: Haohan Xu
Headquarters: New York City, US
Employees: 75
Founded: 2020

AI Insight

AI analysis pending for FRES

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Fresh2 Group Limited do?

Fresh2 Group Limited is a biotechnology company that researches, develops, and markets multi-cancer screening and detection tests using cancer differentiation analysis technology, primarily targeting corporations and life insurance companies in China. In addition to its cancer screening business, the company operates an e-commerce platform connecting food suppliers with supermarket operators and restaurant owners, diversifying its revenue streams and market presence. The company also offers physical checkup packages, genetic testing kits, and skin-care products.

What do analysts say about FRES stock?

Analyst coverage of Fresh2 Group Limited (FRES) is currently limited, reflecting its micro-cap status and speculative nature. Key valuation metrics, such as the negative P/E ratio and significant losses, suggest caution. Growth considerations center on the successful commercialization of its cancer screening technologies and the expansion of its e-commerce platform. Investors should conduct thorough due diligence and carefully assess the company's financial health and competitive landscape before making investment decisions.

What are the main risks for FRES?

Fresh2 Group Limited faces several key risks, including regulatory uncertainties in China, intense competition in both the biotechnology and e-commerce sectors, and the company's significant financial losses. The company's reliance on the Chinese market exposes it to economic and political risks. Additionally, rapid technological advancements in cancer diagnostics could render its existing technologies obsolete. Investors should carefully consider these risks before investing in FRES.